Curated News
By: NewsRamp Editorial Staff
November 13, 2024
Rising Cases of Colorectal Cancer in Young People Spark Collaboration for Innovative Screening Tool
Discuss on Reddit
LinkedIn
Substack
GithubTLDR
- Early detection screening tool ColoAlert by Mainz Biomed has sensitivities exceeding 90% for detecting colorectal cancer, giving a competitive advantage in early intervention.
- ColoAlert via stool samples spots four tumor markers associated with cancer, focusing on precancerous lesions and advanced adenomas, making the method of detection highly accurate.
- Colorectal cancer is a major cause of death in America, killing 50,000 people each year, but early detection with ColoAlert can increase the survival rate to 90% after five years, making a better tomorrow.
- Mainz Biomed's ColoAlert is easy to use, requires small samples, and provides results in a few days, making it a convenient and efficient way to detect colorectal cancer.
Impact - Why it Matters
This news matters because colorectal cancer is no longer just a disease affecting the elderly. The alarming increase in cases among young people calls for urgent attention and innovative solutions for early detection. The collaboration between Mainz Biomed and Thermo Fisher Scientific could potentially save millions of lives by bringing ColoAlert® to the masses.
Summary
Colorectal cancer is on the rise among young people, with cases skyrocketing 500% over the past two decades and a 333% increase in kids aged 10-14. Celebrities like Frankie Muniz and influencers like Petra Smeltzer Starke are raising awareness about this alarming trend. Mainz Biomed and Thermo Fisher Scientific Inc. are teaming up to develop and potentially commercialize ColoAlert®, an early detection screening for colorectal cancer. Clinical trials have shown promising results, with Mainz Biomed gearing up for a clinical FDA trial in the U.S. next year.
ColoAlert® is designed to spot bleeding and non-bleeding tumors through tumor DNA analysis, with sensitivities exceeding 90% for detecting colorectal cancer and over 80% for advanced adenomas. The collaboration between Mainz Biomed and Thermo Fisher Scientific brings them one step closer to bringing this innovative screening tool to the masses, potentially saving millions of lives.
Source Statement
This curated news summary relied on this press release disributed by News Direct. Read the source press release here, Rising Cases of Colorectal Cancer in Young People Spark Collaboration for Innovative Screening Tool
